Accurate diagnosis, particularly the definitive molecular confirmation of ASPSCR1-TFE3 fusion, is paramount before initiating targeted therapies, as it ensures the correct patient population is selected, especially given the overlap in TFE3 positivity with other tumor types. The gene discussed is ASPSCR1; the disease is neoplasm.